How do sex hormones affect the hair cycle?
Human scalp hair grows in three phases: anagen (active growth, lasting years), catagen (transition, lasting days), and telogen (rest, lasting months), followed by shedding. The proportion of follicles in each phase at any time determines overall hair density.
Androgens, particularly dihydrotestosterone (DHT), shorten anagen and push genetically susceptible follicles progressively toward miniaturization — this is androgenetic alopecia, the most common form of hair loss in both sexes. Estrogen has the opposite effect: it prolongs anagen and supports follicle maintenance. This is why women often experience increased hair shedding during postpartum estrogen withdrawal, and why some menopausal women notice thinning as estrogen declines.
Why are some progestins worse for hair loss than others?
The critical variable in HRT-related hair loss is almost always the progestogen component, not the estrogen. Progestogens (synthetic progesterone analogs, or progestins) were developed over decades for different clinical purposes, and their androgenicity varies widely.
High-androgenicity progestins
Older synthetic progestins derived from 19-nortestosterone — including norethindrone (norethisterone), levonorgestrel, norgestrel, and to a lesser extent norgestimate — bind androgen receptors in addition to progesterone receptors. In scalp follicles that are genetically sensitive to androgens, this activity can trigger the same miniaturization pathway as DHT.
These progestins are common in older oral HRT formulations and in many combined oral contraceptives. Women who are already predisposed to female- pattern hair loss (androgenetic alopecia) may notice worsening on these formulations.
Low- or anti-androgenic progestins
Newer synthetic progestins have been developed with more selective progesterone receptor activity:
- Drospirenone: Derived from spironolactone; has anti-androgenic and antimineralocorticoid activity. Used in some modern HRT formulations and combination pills.
- Dienogest: Selective for the progesterone receptor with anti-androgenic properties; primarily used in endometriosis and some European HRT formulations.
- Cyproterone acetate: Potently anti-androgenic; used in parts of Europe and Canada in HRT for women with androgenic symptoms.
For women with hair loss concerns on HRT, switching to one of these formulations (where clinically appropriate) is a recognized strategy.
Bioidentical progesterone
Micronized progesterone (branded as Prometrium in the US, or compounded) is chemically identical to endogenous progesterone. It has substantially lower androgenic activity than the 19-nortestosterone-derived progestins. Most clinicians and the clinical literature regard it as the lower-risk option for women with hair loss concerns. It is not androgenically neutral — progesterone can still be converted to androgenic metabolites by 5-alpha reductase — but the clinical signal for hair loss is much weaker than with androgenic progestins.
Progestogen types compared: androgenicity and hair loss risk
The type of progestogen in an HRT regimen is the key variable for hair loss risk. This table summarizes the androgenic activity of common progestogens used in HRT.
| Progestogen | Androgenicity | Hair loss risk |
|---|---|---|
| Norethindrone (norethisterone) | High | Higher in susceptible individuals |
| Levonorgestrel / Norgestrel | High | Higher in susceptible individuals |
| Micronized progesterone (bioidentical) | Low | Lower; preferred for hair-loss concerns |
| Drospirenone | Anti-androgenic | Low; may be protective |
| Dienogest / Cyproterone acetate | Anti-androgenic | Low; used for androgenic symptoms |
In HRT, the hair-loss risk lives almost entirely in the progestogen — not the estrogen, which generally protects the follicle.
How does estrogen protect against hair loss?
Estradiol (the primary form of estrogen used in HRT) acts on hair follicles through estrogen receptors expressed in the outer root sheath and dermal papilla. Its effects include:
- Prolonging anagen phase duration
- Inhibiting 5-alpha reductase activity, which reduces local DHT conversion
- Supporting the anagen-promoting activity of insulin-like growth factor-1 (IGF-1)
This is why the addition of estrogen in postmenopausal HRT often improves hair density relative to untreated menopause — and why estrogen alone (in women post-hysterectomy who do not require a progestogen) tends to be the formulation least associated with hair loss.
What other causes of hair loss should be ruled out before blaming HRT?
Before attributing hair loss to an HRT formulation, a clinician evaluation should exclude other causes, which are common and often concurrent:
- Thyroid dysfunction: Both hypothyroidism and hyperthyroidism cause diffuse hair shedding (telogen effluvium). TSH is a first-line lab in any hair loss workup.
- Iron deficiency:Ferritin below 30–40 ng/mL is associated with increased telogen shedding even in the absence of anemia. Serum ferritin, not just hemoglobin, should be checked.
- Nutritional deficiencies: Zinc, vitamin D, and biotin deficiencies can contribute. Biotin deficiency is uncommon but worth testing if biotin supplementation is already occurring (it can skew other lab results).
- Telogen effluvium:Physical or psychological stress, surgery, illness, or significant weight loss (including from GLP-1 therapy) can trigger diffuse shedding 2–3 months after the event. This is self-limiting in most cases.
- Autoimmune alopecia: Alopecia areata and other autoimmune hair loss conditions present differently and require different evaluation.
What does a clinician evaluation look like?
A thorough evaluation for HRT-related hair loss should include:
- Lab panel: TSH, free T4, complete blood count, serum ferritin, zinc, vitamin D, DHEA-S, total and free testosterone, SHBG, and sometimes prolactin and ANA depending on clinical history.
- HRT formulation review: Which estrogen, which progestogen, which route (oral, transdermal, vaginal), and current dose.
- Timeline correlation: Did hair loss begin or worsen within weeks to months of starting or changing an HRT component?
- Family history: Androgenetic alopecia has strong genetic components; family history clarifies predisposition.
- Scalp exam or dermatology referral: Pattern distribution (diffuse vs. frontal vs. crown) guides diagnosis.
Based on this evaluation, the clinician can determine whether a formulation switch, dose adjustment, addition of a topical treatment (minoxidil is FDA-approved for female-pattern hair loss), or simply watchful waiting is the appropriate path.
Frequently asked questions
Can HRT cause hair loss in women?
Yes, some forms of hormone replacement therapy can contribute to hair loss. The primary driver is androgenic progestogens (synthetic progestins with testosterone-like activity) that bind androgen receptors in the scalp and trigger follicular miniaturization similar to androgenetic alopecia. Estrogen itself generally supports hair growth, so the net effect depends heavily on which specific hormones are in the regimen.
Does bioidentical progesterone cause hair loss?
Bioidentical progesterone (micronized oral progesterone such as Prometrium, or compounded progesterone) has low androgenic activity compared to synthetic progestins like norethindrone or levonorgestrel. Most clinicians consider it the lower-risk option for patients with hair loss concerns. However, progesterone can still affect 5-alpha reductase conversion to DHT in some individuals; individual response varies.
Does estrogen help with hair loss in menopausal women?
Estrogen prolongs the anagen (growth) phase of the hair cycle and may partially offset androgen-driven follicular miniaturization. Some women notice hair shedding when they discontinue estrogen therapy, particularly during perimenopause when estrogen declines. Estrogen alone (without an androgenic progestogen) is less likely to worsen hair loss and may be protective for some women.
What is the difference between androgenic and non-androgenic progestins?
Androgenic progestins (norethindrone, levonorgestrel, norgestrel, norgestimate) bind androgen receptors and can trigger androgenic effects including scalp hair loss. Non-androgenic or anti-androgenic progestins (drospirenone, dienogest, cyproterone acetate) have neutral or blocking activity at the androgen receptor. Bioidentical progesterone sits in between with low, not zero, androgenic activity.
Should I switch HRT formulations if I am experiencing hair loss?
Hair loss has many causes beyond HRT. A clinician evaluation should first rule out thyroid dysfunction, iron deficiency, other nutritional deficiencies, autoimmune alopecia, and stress-related telogen effluvium before attributing it to the HRT regimen. If the HRT formulation is identified as the likely driver after clinical assessment, switching to a lower-androgenic progestogen or bioidentical progesterone is a reasonable next step.
Can testosterone prescribed as part of HRT cause hair loss?
Testosterone therapy in women (used for libido support) can contribute to androgenetic alopecia in women who are genetically predisposed to DHT sensitivity at scalp follicles. This is dose-dependent and individual. Regular monitoring and dose adjustment is part of responsible testosterone prescribing for women.